Company attributes
Industry
B2X
CEO
Pitchbook URL
Legal Name
GNI Group Ltd.
Number of Employees (Ranges)
1 – 100
Email Address
info@hydroxyapatite.com0
inquiries@cullgen.com0
infojapan@gnipharma.com0
bd@shanghaigenomics.com0
Phone Number
+8621508027860
+151088305000
+8610847829350
+813621436000
Number of Employees
6290
Full Address
901 Grayson Street, Suite 101, Berkeley CA 947100
T1-B-2508, 10 Beijing Wangjing street, Chaoyang District, Beijing, 100102, P. R. China0
Room 201-B106 2nd Floor,Ligang Building Annex, 82# West No.2 Avenue,Free Trade Zone, Tianjin 300308 P.R. China0
Nihonbashi-Honcho YS Bldg. 3F 2-2-2 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-0023, Japan0
Bldg.6,230 ChuanHong Road, ChuanSha,PuDong New Area, Shanghai,China,201202.0
Investors
Founded Date
November 2001
0Fax Number
+8621508027830
+813621436680
+8610888622480
+151088305110
Stock Symbol
2160
Exchange
Patents Assigned (Count)
1
Country
Headquarters
Other attributes
Company Operating Status
Active
Overview
GNI Group Ltd. is a company operating in the pharmaceutical industry, based in Tokyo, Japan. Having been founded in November 2001, the company is currently active and listed on the Tokyo Stock Exchange with the stock symbol 2160. GNI is a B2B organization with a workforce of 629 employees.
Ying Luo serves as the CEO of GNI Group Ltd.. The company has a significant presence in other countries, including China and the United States. In addition to its headquarters in Tokyo, GNI maintains offices in Berkeley, California, Shanghai, San Diego, Tianjin, and Beijing.
GNI has been assigned one patent. They are also linked to the University of Tokyo Edge Capital as an investor in the company.
Timeline
No Timeline data yet.
Funding Rounds
Products
Acquisitions
SBIR/STTR Awards
Patents
Further Resources
No Further Resources data yet.
